Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Biochem Biophys Res Commun. 2023 Oct 20;678:135-143. doi: 10.1016/j.bbrc.2023.08.014. Epub 2023 Aug 14.
Hematological malignancies(HMs) are highly heterogeneous diseases with globally rising incidence. Despite major improvements in the management of HMs, conventional therapies have limited efficacy, and relapses with high mortality rates are still frequent. Cordycepin, a nucleoside analog extracted from Cordyceps species, represents a wide range of therapeutic effects, including anti-inflammatory, anti-tumor, and anti-metastatic activities. Cordycepin induces apoptosis in different subtypes of HMs by triggering adenosine receptors, death receptors, and several vital signaling pathways such as MAPK, ERK, PI3K, AKT, and GSK-3β/β-catenin. This review article summarizes the impact of utilizing cordycepin on HMs, and highlights its potential as a promising avenue for future cancer research based on evidence from in vitro and in vivo studies, as well as clinical trials.
血液系统恶性肿瘤（HMs）是一种高度异质性疾病，全球发病率呈上升趋势。尽管 HMs 的治疗有了重大进展，但传统疗法的疗效有限，且仍经常复发，死亡率高。蛹虫草素是一种从虫草属中提取的核苷类似物，具有广泛的治疗作用，包括抗炎、抗肿瘤和抗转移活性。蛹虫草素通过触发腺苷受体、死亡受体和几条重要的信号通路，如 MAPK、ERK、PI3K、AKT 和 GSK-3β/β-catenin，诱导不同亚型 HMs 的细胞凋亡。本文综述了利用蛹虫草素治疗 HMs 的影响，并根据体外和体内研究以及临床试验的证据，强调了其作为未来癌症研究有希望的途径的潜力。
